Lykan Bioscience, a United States-based contract Manufacturing Services Organisation and provider of the first true end-to-end solution for the manufacture of cell-based therapies, has named Keith McCormick as its new chief financial officer, it was reported on Monday.

In the new role, McCormick will be responsible for the integrity of the company's financial reporting and business control processes while collaborating with the leadership team in all aspects of the company's management, including strategy, contracting, investment, operations management and customer satisfaction.

McCormick has served as a consultant to emerging biotechnology companies. He has also served as VP of Finance at Patheon Pharmaceuticals.